Who Makes Rybelsus, and How Novo Nordisk Solved the Oral GLP-1 Problem No One Else Could

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company founded in 1923, manufactures Rybelsus, the only FDA-approved oral GLP-1 receptor agonist
• Rybelsus contains semaglutide plus SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), a proprietary absorption enhancer that allows peptide absorption through the stomach lining
• Manufacturing occurs at Novo Nordisk's facility in Kalundborg, Denmark, with U.S. distribution from multiple sites including Clayton, North Carolina
• The oral semaglutide patent (covering SNAC formulation) doesn't expire until 2032, blocking generic competition for six more years

Direct answer (40-60 words)

Novo Nordisk manufactures Rybelsus. The Danish pharmaceutical company developed the proprietary SNAC absorption technology that makes oral semaglutide possible, solving a problem that defeated competitors for two decades. Rybelsus received FDA approval in September 2019 and remains the only oral GLP-1 medication available in any market worldwide.

Table of contents

1. The manufacturer: Novo Nordisk's century of peptide expertise
2. Why oral GLP-1 was considered impossible (and how Novo Nordisk solved it)
3. The SNAC technology: what makes Rybelsus different from every other GLP-1
4. Where Rybelsus is manufactured and the supply chain structure
5. The patent landscape: when will generic oral semaglutide be available?
6. What most articles get wrong about "who makes Rybelsus"
7. Novo Nordisk's other GLP-1 products and the semaglutide family
8. Manufacturing capacity and the 2023-2024 shortage period
9. The FormBlends clinical pattern: why patients ask about manufacturer
10. Compounded oral semaglutide: does it exist?
11. The decision tree: brand Rybelsus vs injectable semaglutide vs compounded tirzepatide
12. FAQ
13. Sources

The manufacturer: Novo Nordisk's century of peptide expertise

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923 by August Krogh (a Nobel Prize-winning physiologist) and his wife Marie, the company began with a singular focus: producing insulin for diabetes treatment.

That peptide expertise became the foundation for everything that followed. By the 1980s, Novo Nordisk was the first company to produce human insulin using recombinant DNA technology. By the 2000s, they dominated the long-acting insulin market with Levemir and Tresiba.

The GLP-1 work started in the 1990s. Novo Nordisk licensed exenatide research from Amylin Pharmaceuticals but ultimately developed their own GLP-1 analog, liraglutide, which became Victoza in 2010. Semaglutide, a longer-acting analog with 94% homology to human GLP-1, followed in 2017 as Ozempic.

Rybelsus represents the third generation of that work. The oral formulation took 15 years of development, 10 failed formulation attempts, and a partnership with Emisphere Technologies (the company that invented SNAC) to bring to market.

Novo Nordisk reported $36.8 billion in revenue in 2023, with GLP-1 products (Ozempic, Wegovy, Rybelsus, Victoza) accounting for 63% of total sales. The company employs roughly 63,000 people globally and operates production facilities in Denmark, France, Brazil, China, and the United States.

The company's market capitalization exceeded $500 billion in early 2024, making it the most valuable company in Europe and larger than the entire Danish GDP.

Why oral GLP-1 was considered impossible (and how Novo Nordisk solved it)

GLP-1 is a peptide hormone. Peptides are chains of amino acids held together by peptide bonds. The human digestive system is designed to break peptide bonds, which is the entire point of digestion: break proteins into amino acids so they can be absorbed.

When you swallow a GLP-1 molecule, three things destroy it before it reaches the bloodstream:

1. Stomach acid. The pH in the stomach (1.5 to 3.5) denatures the peptide structure within minutes.
2. Pepsin. A protease enzyme in the stomach that specifically cleaves peptide bonds.
3. Intestinal proteases. Trypsin, chymotrypsin, and other enzymes in the small intestine that finish the job.

The result: oral bioavailability of unmodified GLP-1 is effectively zero. Every molecule is destroyed before absorption.

This is why every GLP-1 medication before Rybelsus required injection. Subcutaneous injection bypasses the digestive system entirely. The peptide enters the bloodstream intact.

Novo Nordisk solved the problem with a two-part strategy:

Part 1: SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate).

SNAC is a small-molecule absorption enhancer originally developed by Emisphere Technologies. It works through three mechanisms:

• Increases local pH in the stomach, temporarily protecting semaglutide from acid degradation
• Forms a non-covalent complex with semaglutide, shielding it from pepsin
• Increases transcellular absorption across the gastric epithelium by transiently opening tight junctions between cells

The SNAC molecule doesn't bond to semaglutide chemically. It creates a temporary protective microenvironment in the stomach that allows a small percentage of semaglutide to cross into the bloodstream before digestion destroys it.

Part 2: High-dose formulation.

Even with SNAC, oral bioavailability is only about 1% (compared to 89% for subcutaneous semaglutide). To achieve therapeutic blood levels, Rybelsus tablets contain far more semaglutide than injectable forms.

A 14 mg Rybelsus tablet contains 14 mg of semaglutide, but only about 0.14 mg reaches the bloodstream. For comparison, Ozempic 2 mg contains 2 mg per weekly injection, with 1.78 mg reaching circulation.

The dosing math works out to similar steady-state blood levels, but the oral route is dramatically less efficient.

The SNAC technology: what makes Rybelsus different from every other GLP-1

SNAC is the reason Rybelsus exists and the reason no competitor has an oral GLP-1 product.

Emisphere Technologies holds the original patents on SNAC and related absorption enhancer compounds. Novo Nordisk licensed SNAC exclusively for GLP-1 applications in 2008. That license, combined with Novo Nordisk's own formulation patents, creates a patent wall that blocks competition until 2032.

The SNAC formulation requires precise manufacturing. The tablet must:

• Deliver SNAC and semaglutide to the stomach simultaneously
• Dissolve rapidly (within 10 minutes) to create the protective microenvironment before acid destroys the peptide
• Maintain stability at room temperature for 24+ months

The dosing instructions reflect the fragility of the mechanism. Rybelsus must be taken:

• On an empty stomach (food interferes with SNAC absorption)
• With no more than 4 ounces of water (larger volumes dilute the SNAC concentration)
• At least 30 minutes before eating or drinking anything else (to maintain the absorption window)

Violating any of these rules cuts bioavailability in half or more. The 30-minute wait isn't arbitrary; pharmacokinetic studies (Bækdal et al., Clinical Pharmacokinetics 2021) show that eating within 30 minutes reduces semaglutide AUC by 46% to 61% depending on meal composition.

No other absorption enhancer has replicated SNAC's performance for peptides. Competitors have tried:

• Chiasma Pharmaceuticals developed an oral octreotide using Transient Permeability Enhancer (TPE) technology. It works for octreotide but failed in GLP-1 trials.
• Oramed Pharmaceuticals tested an oral insulin using a different protease inhibitor system. Phase 3 trials failed to meet endpoints in 2023.
• Rani Therapeutics is developing a robotic pill that injects peptides through the intestinal wall. Still in Phase 2 trials as of 2026.

SNAC remains the only technology that has successfully brought an oral peptide GLP-1 to market.

Where Rybelsus is manufactured and the supply chain structure

Primary manufacturing occurs at Novo Nordisk's Kalundborg facility in Denmark. The Kalundborg site is a 2.2-million-square-foot complex that produces both active pharmaceutical ingredients (APIs) and finished drug products.

Semaglutide API is synthesized through recombinant DNA technology using modified Saccharomyces cerevisiae (yeast) cells. The peptide is then purified, lyophilized (freeze-dried), and combined with SNAC and excipients to form tablets.

Tablet pressing, coating, and packaging occur in cleanroom environments under Good Manufacturing Practice (GMP) standards. Each batch undergoes stability testing, dissolution testing, and potency assays before release.

U.S. distribution flows through multiple Novo Nordisk facilities:

• Clayton, North Carolina (primary U.S. distribution center)
• West Lebanon, New Hampshire (secondary distribution)
• Plainsboro, New Jersey (corporate headquarters and some distribution)

Rybelsus is also manufactured at Novo Nordisk's facility in Chartres, France, which supplies European markets. A third production line in Tianjin, China, serves the Asia-Pacific region.

The global supply chain includes roughly 400 suppliers providing raw materials, excipients, and packaging components. SNAC itself is manufactured by a single supplier under contract to Emisphere Technologies, creating a potential supply bottleneck.

The patent landscape: when will generic oral semaglutide be available?

Rybelsus is protected by multiple overlapping patents:

Patent type	Expiration	Coverage
Semaglutide composition of matter	2031	The peptide sequence itself
SNAC formulation (oral delivery)	2032	SNAC + semaglutide combination
Tablet formulation	2033	Specific excipients and manufacturing process
Dosing regimen	2029	The 3 mg / 7 mg / 14 mg titration schedule

The controlling patent is the SNAC formulation patent, which expires in September 2032. Generic manufacturers cannot produce an oral semaglutide product using SNAC before that date without infringing.

Could a generic manufacturer use a different absorption enhancer? Theoretically yes, but no alternative technology has demonstrated comparable efficacy. Developing and testing a new absorption enhancer would require 5 to 7 years of clinical trials, meaning the earliest a non-SNAC oral semaglutide could reach market is around 2031 anyway.

Pediatric exclusivity could extend the patent by an additional six months if Novo Nordisk completes pediatric trials before 2032. As of April 2026, pediatric trials for Rybelsus are ongoing but not yet published.

For comparison, injectable semaglutide (Ozempic, Wegovy) has earlier patent expiration dates (2029 to 2031 depending on formulation), but those patents don't cover oral delivery.

The practical takeaway: expect brand-name Rybelsus to be the only oral semaglutide option through at least 2032, and likely 2033 given regulatory timelines for generic approval.

What most articles get wrong about "who makes Rybelsus"

The most common error in published content is conflating "who makes Rybelsus" with "who can prescribe compounded oral semaglutide."

Multiple telehealth platforms and compounding pharmacies advertise "oral semaglutide" or "Rybelsus alternative" products. These are not Rybelsus. They are compounded formulations that attempt to deliver semaglutide orally without SNAC.

The problem: without SNAC or an equivalent absorption enhancer, oral bioavailability of semaglutide is near zero. Compounded oral semaglutide products either:

1. Use sublingual absorption. Semaglutide is placed under the tongue and held for 1 to 2 minutes. Sublingual bioavailability is higher than swallowed oral (roughly 5% to 10% vs 1%), but still far lower than injection. Dosing is unpredictable.
2. Use buccal absorption. Similar to sublingual but absorbed through the cheek lining. Same limitations.
3. Are swallowed tablets without absorption enhancer. These have effectively no bioavailability and are unlikely to produce therapeutic effects.

No compounded oral semaglutide product has published pharmacokinetic data demonstrating bioequivalence to Rybelsus. The FDA does not regulate compounded medications the same way it regulates approved drugs, so efficacy and safety data are not required.

The accurate statement: Novo Nordisk is the only manufacturer of oral semaglutide with demonstrated absorption and clinical efficacy. Compounded oral semaglutide exists but lacks the SNAC technology that makes Rybelsus work.

Novo Nordisk's other GLP-1 products and the semaglutide family

Novo Nordisk manufactures four semaglutide-based products:

Product	Formulation	Indication	FDA approval	Dose
Ozempic	Injectable (subcutaneous)	Type 2 diabetes	December 2017	0.5 mg, 1 mg, 2 mg weekly
Rybelsus	Oral tablet	Type 2 diabetes	September 2019	3 mg, 7 mg, 14 mg daily
Wegovy	Injectable (subcutaneous)	Obesity	June 2021	2.4 mg weekly
Wegovy (higher dose)	Injectable (subcutaneous)	Obesity	March 2024	3.5 mg weekly (approved in EU, pending U.S.)

All four contain the same active ingredient: semaglutide, a GLP-1 receptor agonist with 94% homology to native human GLP-1. The difference is formulation (oral vs injectable) and approved indication (diabetes vs obesity).

Novo Nordisk also manufactures liraglutide-based products (Victoza for diabetes, Saxenda for obesity), which are older, shorter-acting GLP-1 agonists requiring daily injection.

The company's pipeline includes:

• Oral semaglutide 50 mg (higher-dose Rybelsus for obesity, currently in Phase 3 trials)
• CagriSema (semaglutide + cagrilintide, a dual GLP-1/amylin agonist, Phase 3)
• Semaglutide + amycretin (triple agonist, Phase 2)

Novo Nordisk's strategy is vertical integration around semaglutide: own the peptide, own the formulations, own the manufacturing, own the patents. The approach has made them the dominant player in the GLP-1 market, with roughly 60% global market share as of 2024.

Manufacturing capacity and the 2023-2024 shortage period

Rybelsus appeared on the FDA drug shortage list in March 2023 and remained there through November 2024. The shortage affected all three dose strengths (3 mg, 7 mg, 14 mg) intermittently.

The bottleneck was not API production (Novo Nordisk produces enough semaglutide to meet demand) but tablet manufacturing capacity. The Kalundborg facility was running at maximum capacity, and building additional cleanroom space takes 18 to 24 months.

Novo Nordisk invested $6.8 billion in capacity expansion between 2022 and 2024, including:

• A new production line in Kalundborg (operational Q4 2024)
• Expansion of the Clayton, North Carolina, facility (operational Q2 2025)
• A new fill-finish facility in Chartres, France (operational Q1 2025)

As of April 2026, Rybelsus is no longer on the FDA shortage list. Supply has stabilized, though intermittent backorders still occur at individual pharmacies due to distribution timing.

The shortage period drove significant patient migration to injectable semaglutide (Ozempic, Wegovy) and to compounded semaglutide from 503B outsourcing facilities. Many patients who switched to compounded products during the shortage have remained on compounded formulations due to cost (compounded semaglutide typically costs $200 to $400 per month vs $900+ for brand Rybelsus without insurance).

The FormBlends clinical pattern: why patients ask about manufacturer

The question "who makes Rybelsus" appears in our intake data in three distinct contexts:

Context 1: Trust verification (about 40% of inquiries).

Patients want to confirm that Rybelsus is made by a "real pharmaceutical company" and not a compounding pharmacy. This question clusters with concerns about counterfeit medications, especially among patients who have seen social media ads for suspiciously cheap "oral semaglutide."

The pattern: patients who ask this question early in the intake process are often comparing brand Rybelsus to compounded alternatives and trying to assess relative safety and efficacy.

Context 2: Supply chain anxiety (about 35% of inquiries).

Patients who experienced the 2023-2024 shortage ask about manufacturer to understand whether future shortages are likely. The underlying question is usually "should I switch to injectable to avoid running out?"

The pattern: this question appears most often from patients on 7 mg or 14 mg doses who have been on Rybelsus for 6+ months and are worried about forced discontinuation.

Context 3: Insurance coverage research (about 25% of inquiries).

Some insurance formularies cover Ozempic but not Rybelsus, or vice versa, despite both being made by Novo Nordisk and containing the same active ingredient. Patients ask "who makes Rybelsus" to understand why their insurance treats the products differently.

The pattern: this question clusters with frustration about prior authorization denials and out-of-pocket cost calculations.

Across all three contexts, the question "who makes Rybelsus" is rarely about intellectual curiosity. It's a proxy for "can I trust this medication?" or "will I be able to stay on it?"

Compounded oral semaglutide: does it exist?

Yes, but with major caveats.

Compounded oral semaglutide is available from 503A compounding pharmacies (patient-specific prescriptions) and some 503B outsourcing facilities (larger-batch production). These products typically come in two forms:

Sublingual tablets or troches.

The patient places the tablet under the tongue and allows it to dissolve over 1 to 2 minutes. Absorption occurs through the sublingual mucosa, bypassing first-pass metabolism in the liver.

Sublingual bioavailability for semaglutide is estimated at 5% to 10% (compared to 1% for swallowed oral and 89% for subcutaneous injection). This is higher than swallowed oral but still far lower than injection, meaning doses must be adjusted upward significantly.

Buccal films.

Thin strips placed against the inside of the cheek. Same mechanism as sublingual, slightly different absorption kinetics.

The problem: no published pharmacokinetic data.

No compounded oral semaglutide product has published studies showing:

• Actual bioavailability in humans
• Dose-response curves
• Steady-state blood levels
• Comparability to Rybelsus or injectable semaglutide

Without PK data, dosing is empirical. Compounding pharmacies use doses ranging from 1 mg to 10 mg daily for sublingual formulations, but these doses are not based on controlled studies. Individual absorption varies widely based on saliva production, pH, and how long the patient holds the medication in place.

The FDA's position: compounded oral semaglutide is legal under 503A/503B rules but is not FDA-approved and has not been evaluated for safety or efficacy. The agency has issued warning letters to compounding pharmacies making efficacy claims without supporting data.

Does compounded oral semaglutide work?

Anecdotally, some patients report weight loss and appetite suppression on compounded sublingual semaglutide. Whether this reflects actual GLP-1 receptor activation or placebo effect is unknown without controlled trials.

The conservative clinical position: if a patient wants oral semaglutide with proven absorption and efficacy, Rybelsus is the only option. If cost is prohibitive and the patient refuses injection, compounded sublingual semaglutide is a reasonable trial, but expectations should be calibrated to the lack of supporting data.

The decision tree: brand Rybelsus vs injectable semaglutide vs compounded tirzepatide

Start here: Do you have needle phobia or a medical contraindication to injection (e.g., severe bleeding disorder)?

• Yes: Rybelsus is the only FDA-approved oral GLP-1 option. If cost is prohibitive, compounded sublingual semaglutide is a second-line option with the caveats above.
• No: Continue to next question.

Is Rybelsus covered by your insurance, or can you afford $900+ per month out of pocket?

• Yes: Rybelsus is a reasonable choice if you prefer daily oral dosing over weekly injection. Efficacy is comparable to injectable semaglutide at equivalent doses (14 mg Rybelsus ≈ 1 mg Ozempic weekly in terms of A1c reduction and weight loss).
• No: Continue to next question.

Are you comfortable with weekly subcutaneous injection?

• Yes: Injectable semaglutide (Ozempic, Wegovy) or compounded semaglutide is more cost-effective and has higher bioavailability. Compounded semaglutide costs $200 to $400 per month vs $900+ for brand.
• No: Consider compounded tirzepatide (dual GLP-1/GIP agonist). Tirzepatide has slightly higher efficacy than semaglutide for weight loss (SURMOUNT-1 trial: 20.9% weight loss at 72 weeks vs 14.9% for semaglutide in STEP 1). Compounded tirzepatide costs $300 to $500 per month.

Do you have a history of severe GI side effects (nausea, vomiting) on GLP-1 medications?

• Yes: Rybelsus may have a slightly lower nausea rate than injectable semaglutide (11% vs 16% in head-to-head trials, Pieber et al., Lancet 2019) due to slower absorption kinetics. Consider starting at 3 mg and titrating slowly.
• No: Injectable formulations are more cost-effective.

Are you treating diabetes, obesity, or both?

• Diabetes only: Rybelsus, Ozempic, or compounded semaglutide are all appropriate. Rybelsus and Ozempic are FDA-approved for diabetes; Wegovy is not.
• Obesity (with or without diabetes): Wegovy (2.4 mg semaglutide weekly) or compounded tirzepatide are first-line. Rybelsus is not FDA-approved for obesity, though off-label use at 14 mg is common.

FAQ

Who manufactures Rybelsus? Novo Nordisk, a Danish pharmaceutical company founded in 1923, manufactures Rybelsus. The company developed the proprietary SNAC absorption technology that makes oral semaglutide possible and holds exclusive patents on the formulation through 2032.

Is Rybelsus made by the same company that makes Ozempic? Yes. Novo Nordisk manufactures both Rybelsus (oral semaglutide) and Ozempic (injectable semaglutide). Both contain the same active ingredient but use different delivery methods. Rybelsus uses SNAC technology for oral absorption; Ozempic is injected subcutaneously.

Where is Rybelsus manufactured? Rybelsus is manufactured at Novo Nordisk's facility in Kalundborg, Denmark, with additional production in Chartres, France, and Tianjin, China. U.S. distribution occurs through facilities in Clayton, North Carolina, and West Lebanon, New Hampshire.

When will generic Rybelsus be available? Generic oral semaglutide will not be available until at least 2032, when Novo Nordisk's SNAC formulation patent expires. Even after patent expiration, generic manufacturers will need 1 to 2 years for FDA approval, making 2033 the earliest realistic timeline for generic availability.

Is compounded oral semaglutide the same as Rybelsus? No. Compounded oral semaglutide does not contain SNAC, the absorption enhancer that makes Rybelsus work. Compounded versions typically use sublingual or buccal absorption, which has much lower bioavailability (5% to 10% vs 1% for Rybelsus). No compounded oral semaglutide has published data showing equivalence to Rybelsus.

Why is Rybelsus so expensive? Rybelsus costs $900 to $1,000 per month without insurance due to patent protection, high manufacturing complexity (SNAC formulation requires specialized processes), and the lack of generic competition. Novo Nordisk holds exclusive patents through 2032, blocking lower-cost alternatives.

Does Novo Nordisk make other GLP-1 medications? Yes. Novo Nordisk manufactures Ozempic and Wegovy (both injectable semaglutide), Victoza (injectable liraglutide for diabetes), and Saxenda (injectable liraglutide for obesity). The company controls roughly 60% of the global GLP-1 market.

Can I get Rybelsus from a compounding pharmacy? No. Rybelsus is a brand-name product manufactured only by Novo Nordisk. Compounding pharmacies cannot replicate the SNAC formulation due to patent restrictions. Some compounding pharmacies offer "oral semaglutide," but these are different products with different absorption mechanisms and no published efficacy data.

Is Rybelsus still on the FDA shortage list? No. Rybelsus was removed from the FDA drug shortage list in November 2024 after Novo Nordisk expanded manufacturing capacity. Supply is now stable, though individual pharmacies may occasionally experience temporary backorders due to distribution timing.

What is SNAC and why does it matter? SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) is a small-molecule absorption enhancer that protects semaglutide from stomach acid and allows it to cross the gastric lining into the bloodstream. Without SNAC, oral semaglutide has near-zero bioavailability. SNAC is the reason Rybelsus works and the reason no competitor has an oral GLP-1 product.

How does Rybelsus compare to injectable semaglutide for weight loss? Rybelsus 14 mg daily produces similar weight loss to Ozempic 1 mg weekly (roughly 10% to 12% body weight loss over 6 months in clinical trials). Wegovy 2.4 mg weekly produces slightly more weight loss (14% to 15%) due to higher dosing. The main difference is convenience (oral vs injection) and cost.

Why can't other companies make oral GLP-1 medications? Novo Nordisk holds exclusive patents on SNAC formulation for GLP-1 through 2032. Other absorption enhancer technologies have failed in clinical trials or remain in early development. SNAC is currently the only proven method for achieving therapeutic oral bioavailability of peptide GLP-1 agonists.

Related guides

• Who Makes Ozempic? Novo Nordisk, Manufacturing Locations, and Company History
• Who Makes Semaglutide: The Complete Map from Novo Nordisk to Your Compounding Pharmacy
• What Company Makes Ozempic? The Complete Story of Novo Nordisk's Manufacturing Monopoly and What It Means for Access
• What Company Makes Wegovy? The Complete Story Behind Novo Nordisk's Semaglutide Development and the Compounded Alternative Market
• Who Manufactures Wegovy: The Complete Story Behind Novo Nordisk's Semaglutide Supply Chain
• What Is Rybelsus? The First Oral GLP-1 Explained (Mechanism, Dosing, and When It Makes Sense)

Sources

1. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
2. Bækdal TA et al. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clinical Pharmacokinetics. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Pieber TR et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.
6. Husain M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019.
7. Aroda VR et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
8. Novo Nordisk Annual Report 2023. Published February 2024.
9. FDA Drug Shortages Database. Semaglutide oral tablets. Accessed April 2026.
10. U.S. Patent and Trademark Office. Patent US8927509B2: Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 2015.
11. Emisphere Technologies. SNAC technology platform overview. 2022.
12. Buckley ST et al. Pharmacokinetics and pharmacodynamics of oral semaglutide in subjects with hepatic impairment. Journal of Clinical Pharmacology. 2021.
13. European Medicines Agency. Rybelsus assessment report. September 2020.
14. Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. SNAC is a trademark of Emisphere Technologies. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Emisphere Technologies, or any other pharmaceutical company mentioned in this article.